GSK

GSK plc sits at a peculiar inflection point in European pharma. The company that once stumbled through a decade of strategic ambiguity, caught between consumer healthcare, vaccines, and specialty pharmaceuticals, has emerged from its 2022 demerger of Haleon as a fundamentally different entity. The numbers tell the story of a company accelerating: FY2025 revenue reached GBP 32.7 billion, up from GBP 31.4 billion the prior year, while net income surged from GBP 2.6 billion to GBP 5.7 billion. That is not incremental improvement. That is a structural step-change in profitability.

Yet the market continues to price GSK as if the past decade's mediocrity is the permanent condition. At approximately GBP 21.70 per share and a market capitalization of GBP 86.7 billion, the stock trades at roughly 12.9 times earnings, a valuation that implies skepticism about the durability of recent improvements. The central analytical question is not whether GSK can grow. It clearly is growing. The question is whether the market has correctly assessed the permanence of the structural advantages that the post-Haleon GSK now commands, or whether it is still discounting a company that no longer exists.

The L17X insight here is counterintuitive: GSK's competitive moat is not primarily about any single blockbuster drug. It is about the integration of manufacturing infrastructure, regulatory relationships, and distribution networks across vaccines and HIV therapeutics that makes the cost of competitive entry prohibitively high for all but two or three global peers. This is a company that does not need to disrupt because the barriers it has built over decades compound with each passing year of regulatory and production complexity. Competitors do not attack GSK's position. They route around it.